CooperCompanies trims 2026 revenue guidance after Q2 beat, shares react to outlook shift
28.06.2026 - 11:44:18 | ad-hoc-news.de
By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-28, 11:43.
CooperCompanies (US21664P1039) reported a stronger-than-expected fiscal second quarter 2026, while modestly trimming its full-year revenue outlook as its core eye care and fertility businesses continue to expand on the NYSE listing.Zacks earnings recap
What the Q2 figures show
For fiscal Q2 2026, CooperCompanies posted adjusted earnings per share of 1.21 dollars, up 26 percent year on year and ahead of the Zacks consensus estimate of 1.10 dollars by around 10 percent.Zacks earnings recap Quarterly revenues reached approximately 1.08 billion dollars, also beating expectations and reflecting continued demand in both contact lenses and specialty surgical products.Zacks earnings recap
Guidance adjustment and analyst lens
Despite the Q2 beat, CooperCompanies now guides fiscal 2026 revenues to a range of 4.285 to 4.321 billion dollars, slightly below the prior range of 4.306 to 4.346 billion dollars, while still implying organic growth of 3.5 to 4.5 percent versus the prior year.Zacks earnings recap Zacks notes the consensus revenue estimate at about 4.32 billion dollars and a full-year adjusted EPS expectation of 4.58 to 4.66 dollars, close to the 4.62-dollar consensus benchmark.Zacks earnings recap
More news and data on CooperCompanies
All recent headlines, price data and regulatory filings on the CooperCompanies shares can be found in the dedicated topic section and via the company’s investor relations site.
The product mix behind the numbers
CooperCompanies generates a large share of its revenue through its CooperVision contact lens portfolio, where daily disposable lenses such as MyDay have delivered double-digit growth and specialty myopia management lens MiSight rose about 24 percent year on year in Q2 2026.Zacks earnings recap Its CooperSurgical unit contributed revenue of around 358 million dollars in the quarter, supported by fertility-related products and the Witness diagnostic line, with the segment’s full-year revenue guidance slightly lifted compared with the prior range.Zacks earnings recap
Where the stock trades today
CooperCompanies shares (US21664P1039) trade on the NYSE at about 100.00 dollars as of 2026-06-28, 11:43.
CooperCompanies share data in brief
- Company: CooperCompanies Inc.
- ISIN: US21664P1039
- WKN: 867101
- Ticker: COO
- Trading venue: NYSE
- Price (as of 2026-06-28, 11:43): 100.00 USD
- Market cap: 4.80 billion USD (as of 2026-06-28)
- Sector / industry: Health Care / Medical Devices
- Index membership: S&P 500
- Next earnings date: 2026-09-05
This article is for informational purposes only and does not contain investment advice, buy or sell recommendations, or individualized financial guidance. All figures and dates are based on publicly available sources believed to be reliable at the time of writing but may change without notice.
